

Results Presentation of FY2021 1Q



Possibility of chemistry

(the 1st 3months of the Fiscal year ending March 2022)

Securities code: 4061

Denka Co. ,Ltd

August 6, 2021

1

FY2021 1Q Results

a) Summary	(Yea	ar-on-Y	'ear)	03
b) Change Factors	(11)	04
c) Graph of Operating Income Change Factors	(11)	05
d) By Segment	(11)	06
e) Change Factors By Segment	(11)	07-08

2 FY2021 Earnings Forecast

a) Summary	(vs Forecast at the	e beginr	ning, Year-on	-Year)	10
b) 1H:Change Factors		(vs For	ecast at the beg	ginning)	11
c) 1H: Graph of Operating Inco	ome Change Factors	(11)	12
d) 1H:By Segment		(11)	13
e) 1H: Change Factors By Segment			11)	14-17
f) Full year:By Segment		(11)	18
g) Key Performance Indicate	ors				19
h) Shareholder Returns					20
i) FY2022 Numerical Targets of I	Denka Value-Up				21

FY2021 1Q Results

FY2021 1Q Results a) Summary (Year-on-Year)

(¥ billions)	FY2020 1Q Actual	FY2021 1Q Actual	Incr. Main factors Decr. of Incr.Decr
Sales	76.2	86.7	+ 10.5 (Detailed below)
Operating Income	4.4	7.7	+ 3.3 (Detailed below)
Operating Margin	5.8%	8.9%	+ 3.2%
Ordinary Income	5.0	7.5	Interest rates, - 0.8 + 2.5 Non-operating income, etc. ← + 2.5
Net income attributable to Owners of parent	4.2	6.2	Extraordinary gains and - 0.5 + 2.0 losses and Corporate tax etc. + 2.0

Despite the lingering negative impact of COVID-19, the Denka Value-Up initiative was successful, resulting in marking record highest operating income for 1Q

		YoY (¥ billions)
Sales	86.7 billion	+ 10.5
1. Volume :R	ecovery of demand from COVID-19 impact	
C	other (xEV-related, semiconductor-related demand growth, etc.)	+ 13.0
2. Pricing : S	yrene-based products sales price revision due to raw material price increase, etc.	+ 5.7
	hange in accounting standards for recognition of revenue Group trading company portion, etc.)	- 8.2
Operating		YoY (¥ billions)
Operating Income	7.7 billion	+ 3.3
1. Volume	Recovery of demand from COVID-19 impact	
	Other (xEV-related, semiconductor-related demand growth, etc.)	+ 6.3
2. Pricing	Styrene-based products sales price revision due to raw material price increase (include impact of currency fluctuations +0.2)	e + 5.7
3. Variable Cost		
Difference	Raw material price increase, etc. (include impact of currency fluctuations +0.2) - 8.0
4. Costs	: Other administrative expenses and manufacturing costs, etc.	- 0.7
	In addition to recovery from the impact of COVID-19,	

demand growth in xEV and semiconductor-related products offset worsening spread

(margin between product sales prices and raw materials prices)

Denka

		+ 5.7				(¥ billions)
	+ 6.3					7.7
4.4			- 8.0	- 0.7	+ 0.0	
	Recovery of demand from COVID-19 impact xEV-related, Semiconductor-related demand growth, etc.	Styrene-based products sales price revision due to raw material price increase, etc.	raw material price increase, etc.	Other administrative expenses and manufacturing costs, etc.	R&D expenses	
FY2020 1Q Actual	Volume	Pricing Include impact of currency fluctuations +0.2	Variable cost difference Include impact of currency fluctuations +0.2	Costs	Advance investment	FY2021 1Q Actual

In addition to recovery from the impact of COVID-19,

demand growth in xEV and semiconductor-related products offset worsening spread

FY2021 1Q Resultsd) By Segment (Year-on-Year)

Sales (¥ billions)	FY2020 1Q Actual	FY2021 1Q Actual	Incr. Decr.	Pricing	Volume	Other*
Electronics & Innovative Products	17.1	21.0	+ 3.9	+ 0.4	+ 4.9	- 1.3
Life Innovation	5.3	6.0	+ 0.7	- 0.2	+ 0.9	- 0.0
Elastomer & Infrastructure Solutions	19.8	24.6	+ 4.8	+ 0.2	+ 5.4	- 0.9
Polymer Solutions	25.3	31.8	+ 6.4	+ 5.4	+ 1.5	- 0.4
Others	8.7	3.5	- 5.2		+ 0.3	- 5.5
Total	76.2	86.7	+10.5	+ 5.7	+ 13.0	- 8.2

*Change in accounting standards for recognition of revenue

Operating Income (¥ billions)	FY2020 1Q Actual	FY2021 1Q Actual	Incr. Decr.	Pricing	Volume	Cost& Others
Electronics & Innovative Products	2.8	4.4	+ 1.6	+ 0.4	+ 2.3	- 1.1
Life Innovation	0.0	0.3	+ 0.3	- 0.2	+ 0.4	+ 0.0
Elastomer & Infrastructure Solutions	0.3	0.1	- 0.2	+ 0.2	+ 2.9	- 3.3
Polymer Solutions	1.3	2.6	+ 1.3	+ 5.4	+ 0.6	- 4.7
Others	0.0	0.4	+ 0.4	-	- 0.0	+ 0.4
Total	4.4	7.7	+ 3.3	+ 5.7	+ 6.3	- 8.7

Expanded sales in Electronics & Innovative Products, and improved spread in Polymer Solutions contributed to increase income

FY2021 1Q Resultse) Change Factors By Segment (Year-on-Year)

Electron	ics & Inno	ovative P	roducts		Operating income main change factors
(¥ billions)	FY2020 1Q Actual	FY2021 1Q Actual	Incr. Decr.	Spherical Alumina	: xEV-related applications and 5G communications-related demand growth
Sales	17.1	21.0	+3.9		Increased shipments due to partial operation beginning of new facilities in Singapore
Operating	2.8	4.4	+1.6	Acetylene Black Fused Silica,	: Strong demand for xEV-related applications and high- voltage cables for offshore wind power generation
Income				Carrier Tape, etc.	: Semiconductor-related demand growth
	Life Inno	ovation			

	Life mind			0	perating income main change factors
(¥ billions)	FY2020 1Q Actual	FY2021 1Q Actual	Incr. Decr.		
Sales	5.3	6.0	+0.7	Rapid Antigen Test COVID-19	: Not sold in 1Q last year ~ quantity difference
Operating Income	0.0	0.3	+0.3	Other test reagents	: Recovery of demand from the impact of COVID-19

Drived by growth of specialty businesses related to xEV, semiconductor, and infectious disease

FY2021 1Q Resultse) Change Factors By Segment (Year-on-Year)

Denka

Elastomer	r & Infras	tructure	Solutions	Operating income main change factors
(¥ billions)	FY2020 1Q Actual	FY2021 1Q Actual	lncr. Decr.	Chloroprene : Sales volumes increased due to recovery of demand from
Sales	19.8	24.6	+4.8	Rubber the impact of COVID-19. However, decreased operation due to a cold spell at DPE and increased raw material
Operating Income	0.3	0.1	-0.2	pricing resulted nearly unchanged from the previous termCement: Income decreased due to lower sales volumes than in the previous term, and a rise in coal prices
F	Polymer	Solutions		Operating income main change factors
(¥ billions)	FY2020 1Q Actual	FY2021 1Q Actual	lncr. Decr.	MS resin (Singapore) : Almost the same shipments as
Sales	25.3	31.8	+6.4	AS, ABS, transparent : Almost the same shipments as AS, ABS, transparent
Operating Income	1.3	2.6	+1.3	resins, etc. Toyokalon : Recovery from impact of COVID-19 during the previous fiscal term
	Oth	ners		Sales main change factors
(¥ billions)	FY2020 1Q Actual	FY2021 1Q Actual	lncr. Decr.	
Sales	8.7	3.5	-5.2	Change in accounting standards for recognition of revenue
Operating Income	0.0	0.4	+0.4	(decrease in sales of Group companies)

Recovery in demand in businesses in our key operations such as chloroprene rubber and performance plastics

Copyright © Denka Co., Ltd. All Rights Reserved. 8

FY2021 Earnings Forecast

FY2021 Earnings Forecast a) Summary (vs Forecast at the beginning, Year-on-Year)

FV2021 1 L

EV2021 E. II

			FY2021 1	H	FY2021 Full year				
(¥ billions)	Initial Forecast	Revised Forecast	Vs. initial Forecast	FY2020 1 H Actual Year- on-year	lnitial Forecast	Revised Forecast	Vs. initial Forecast	,	′ear- i-year
Sales	175.0	185.0	+10.0	160.3 + 24.7	365.0	365.0	± 0.0	354.4 +	10.6
Operating Income	19.0	22.0	+ 3.0	12.1 + 9.9	42.0	42.0	± 0.0	34.7 +	7.3
Operating Margin	10.9%	11.9%	+ 1.0%	7.5% + 4.4%	11.5%	11.5%	± 0.0%	9.8% +	1.7%
Ordinary Income	17.0	20.0	+ 3.0	12.3 + 7.7	39.0	39.0	± 0.0	32.1 +	6.9
Net income attributable to Owners of parent	13.0	15.0	+ 2.0	10.0 + 5.0	29.0	29.0	± 0.0	22.8 +	6.2


1H: Sales, Operating income, Ordinary income, and Net income all revised upward Full year: Initial forecast remains unchanged as of now

Vs. forecast (¥ billions)

Sales	185.0 billion	+10	0.0
	tive factors (Upwards trend in semiconductor-related products and chloroprene rubber) ative factors (Anticipating downward trend in influenza vaccines, etc.)	+	0.5
U 1	vard revision of estimated sales price of COVID-19 rapid antigen test kit ene-based products sales price revision due to raw material price increase	+	9.5
	Vs.	forecast (∉ billions)
Operating Income	22.0 billion	+3	.0
1. Volume	: Anticipating reduced volume of influenza vaccine, etc.	-	0.4
2. Pricing	: Upward revision of estimated sale price of COVID-19 rapid antigen test kit, Styrene-based products sales price revision due to raw material price increase (including impact of currency fluctuations +0.9)	÷	9.5
3. Variable cost			
Difference	: Raw material price increase, etc. (including impact of currency fluctuations -0.	5) -	6.3
4. Costs	: Other administrative expenses and manufacturing costs, etc.	+	0.2
the esti	ng income, a positive difference in sales price including an upward r mated sales price of COVID-19 rapid antigen test kit is expected to e mpact of variable cost difference resulting from a rise in raw materi	xceed	

FY2021 Earnings Forecast
 c) 1H : Graph of Operating Income Change Factor (vs Forecast at the beginning)

Denka



For operating income, a positive difference in sales price including an upward revision of the estimated sales price of COVID-19 rapid antigen test kit is expected to exceed negative impact of variable cost difference resulting from a rise in raw material prices

FY2021 Earnings Forecastd) 1H: By Segment (vs Forecast at the beginning)

Sales (¥ billions)	FY2021 1H Initial Forecast	FY2021 1H Revised Forecast	lncr. Decr.	Pricing	Volume
Electronics & Innovative Products	42.0	43.0	+ 1.0	+ 0.1	+ 0.9
Life Innovation	18.0	24.0	+ 6.0	+ 5.8	+ 0.2
Elastomer & Infrastructure Solutions	50.0	51.0	+ 1.0	+ 0.8	+ 0.2
Polymer Solutions	60.0	62.0	+ 2.0	+ 2.8	- 0.8
Others	5.0	5.0	± 0.0	_	± 0.0
Total	175.0	185.0	+10.0	+ 9.5	+ 0.5

Operating Income (¥ billions)	FY2021 1H Initial Forecast	FY2021 1H Revised Forecast	Incr. Decr.	Pricing	Volume	Cost& Others
Electronics & Innovative Products	8.0	8.0	± 0	+ 0.1	+ 0.8	- 0.9
Life Innovation	5.0	8.5	+ 3.5	+ 5.8	- 1.7	- 0.6
Elastomer & Infrastructure Solutions	1.0	0.5	- 0.5	+ 0.8	+ 0.8	- 2.0
Polymer Solutions	4.5	4.5	± 0.0	+ 2.8	- 0.3	- 2.5
Others	0.5	0.5	± 0.0	_	+ 0.0	- 0.0
Total	19.0	22.0	+ 3.0	+ 9.5	- 0.4	- 6.1

The main factor in the upward revision of operating income : the increasing income of "Life Innovation"

(¥ billions)	FY2021 1H Initial Forecast	FY2021 1H Revised Forecast	Incr. Decr.	_	Pricing	Volume	Cost& Others	_	FY2020 1 H Actual
Sales	42.0	43.0	+ 1.0		+ 0.1	+ 0.9			36.7
Operating Income	8.0	8.0	± 0.0		+ 0.1	+ 0.8	- 0.9		6.6

Sales trends

Spherical alumina	 Increasing xEV-related, 5G communications-related demand is expected in line with the initial forecast
	 Contribution of new facilities in Singapore is also expected in line with the initial forecast
Acetylene black	 Steady demand for xEV-related applications and high-voltage cables for offshore wind power generation, resulting in shipments in line with the initial forecast
Ceramic substrates	• Delayed recovery of demand from electric railways is expected from the impact of COVID-19
Fused silica High-performance film	 Bolstered by expanded demand from 5G communications and data centers, shipments of semiconductor-related products are expected to exceed initial forecasts

<u>Cost</u>

• Higher costs due to increased raw material prices and differences in product mixes

Increasing Operating income is expected in line with initial forecasts owing to higher demand for semiconductor-related products despite increasing costs due to higher raw material prices

(¥ billions)	FY2021 1H Initial Forecast	FY2021 1H Revised Forecast	Incr. Decr.	Pricing	Volume	Cost& Others	_	FY2020 1 H Actual
Sales	18.0	24.0	+ 6.0	+ 5.8	+ 0.2			16.2
Operating Income	5.0	8.5	+ 3.5	+ 5.8	- 1.7	- 0.6		2.4

Sales trends

COVID-19 rapid antigen test kit	 Upward revision of estimated selling price of the initial forecast Although the expansion of demand, including screening tests at senior citizen facilities, was factored into the initial forecast, it is expected to exceed the forecast to some extent due to the supply to the Japanese government.
Other test reagents	 In addition to a recovery of demand in China, increasing other testing demands of COVID-19 patients in Europe and the US, resulting in exceeding expectations
Influenza vaccine	 Shipment volumes may fail to meet initial forecasts at the same level as last year.

While influenza vaccine shipment volumes may fail to meet initial forecasts, COVID-19 rapid antigen test kits will contribute to increase income.

(¥ billions)	FY2021 1H Initial Forecast	FY2021 1H Revised Forecast	lncr. Decr.	Pricing	Volume	Cost& Others	FY2020 1 H Actual
Sales	50.0	51.0	+ 1.0	+ 0.8	+ 0.2		41.8
Operating Income	1.0	0.5	- 0.5	+ 0.8	+ 0.8	- 2.0	-0.1

Sales trends

Chloroprene rubber	 We have seen a temporary slowdown in medical glove applications which have driven demand since the second half of the last fiscal year, but we expect a strong recovery in demand in industrial, adhesive, and automotive applications that will exceed forecasts
Specialty admixtures	 Recovery from the impact of COVID-19 during the previous year is expected in line with initial forecasts
Cement	 Recovery from the impact of COVID-19 during the previous year is expected in line with initial forecasts

<u>Cost</u>

• Price increase in raw materials (butadiene/chlorine (chloroprene rubber), coal (cement), etc.)

Demand for chloroprene rubber is to recover more than expected, however, to be lower than initial forecasts due to recent increases in raw material prices

(¥ billions)	FY2021 1H Initial Forecast	FY2021 1H Revised Forecast	lncr. Decr.	Pricing Volume	Cost& Others	FY2020 1 H Actual
Sales	60.0	62.0	+ 2.0	+ 2.8 - 0.8		50.4
Operating Income	4.5	4.5	± 0.0	+ 2.8 - 0.3	- 2.5	2.9

Sales trends

MS resin	 Demand for use in light guide plates in TVs and monitors and in other applications such as cosmetic containers has remained strong, and is expected to remain in line with initial forecasts Production capacity in Singapore doubled (operation started in July) 							
AS, ABS, transparent resins, etc.	 We expect increased profits due to higher volumes from the market recovery, and from inventory Impact. 							
Food wrapping sheets, Denka Polymers	 Recovered from the impact of COVID-19 during the previous year, but slightly below forecasts 							
Toyokalon	 Recovery from the impact of COVID-19 during the previous year meaning in line with initial forecasts 							
Cost	Price increase in raw materials (ethylene, benzene, etc.)							
As spread will maintain despite increase in raw materials costs,								

As spread will maintain despite increase in raw materials costs, Operating income is to be in line with initial forecasts (1.5× increase QoQ)

Denka

FY2021 Earnings Forecastf) Full year : By Segment (vs Forecast at the beginning)

Denka

	FY2021 1H				FY2021 Full year			
Sales (¥ billions)	FY2021 1H Initial Forecast	FY2021 1H Revised Forecast	Incr. Decr.		FY2021 Initial Forecast	FY2021 Revised Forecast		icr. ecr.
Electronics & Innovative Products	42.0	43.0	+ 1.	0	85.0	85.0	±	0.0
Life Innovation	18.0	24.0	+ 6.	0	40.0	40.0	±	0.0
Elastomer & Infrastructure Solutions	50.0	51.0	+ 1.	0	105.0	105.0	±	0.0
Polymer Solutions	60.0	62.0	+ 2.	0	125.0	125.0	±	0.0
Others	5.0	5.0	± 0.	0	10.0	10.0	±	0.0
Total	175.0	185.0	+10.	0	365.0	365.0	±	0.0
Operating Income (¥ billions)	FY2021 1H Initial Forecast	FY2021 1H Revised Forecast	Incr. Decr		FY2021 Initial Forecast	FY2021 Revised Forecast		ncr. ecr.
Electronics & Innovative Products	8.0	8.0	± 0	.0	17.0	17.0	±	0.0
Life Innovation	5.0	8.5	+ 3	.5	10.5	10.5	±	0.0
Elastomer & Infrastructure Solutions	1.0	0.5	△ 0	.5	4.0	4.0	±	0.0
Polymer Solutions	4.5	4.5	± 0	.0	9.5	9.5	±	0.0
Others	0.5	0.5	± 0	.0	1.0	1.0	±	0.0
Total	19.0	22.0	± 3	.0	42.0	42.0	±	0.0

Initial full-year forecasts in each segment remain unchanged as of now

FY2021 Earnings Forecast g) Key Performance Indicators

(¥ billions)	FY2020 1Q Actual (Apr-Jun)	FY2021 1Q Actual (Apr-Jun)	FY2021 1H Revised Forecast (Apr-Sep)	FY2021 Full-Year Initial Forecast (Apr-Mar)
Investment	71	76	220	430
Depreciation	57	57	115	235
R&D	38	38	80	160
Interest-Bearing Debt	1,422	1,402	1,380	1,370
	FY2020 1Q Actual (Apr-Jun)	FY2021 1Q Actual (Apr-Jun)	FY2021 1H Revised Forecast (Apr-Sep)	FY2021 Full-Year Initial Forecast (Apr-Mar)
Forex (¥/\$)	107.7	109.8	110.0	108.0
Japan Naphtha (¥/KI)	26,000	48,100	50,450	46,000

Continuing strategic investment into specialty businesses

Denka

		FY2017 Actual	FY2018 Actual	FY2019 Actual	FY2020 Actual	FY2021 Initial Forecast	
Net Income (billion)		23.0	25.0	22.7	22.8	29.0	
Dividend per share*	(¥)	105.0	120.0	125.0	125.0	135.0	
						Mid-term 65.0 End 70.0	
Dividend	(billion)	9.2	10.5	10.8	10.8	11.6	
Shareholders Return		40%	42%	48%	47%	40%	
Stock Purchase	(billion)	2.3	2.1	-	-	Continue our policy targeting	
Total Return	(billion)	11.5	12.6	10.8	10.8	a total return ratio of 50% through share buybacks	
Total Return Ratio		50%	50%	48%	47%		
Depreciation		24.6	22.9	22.5	22.9	23.5	
Investment & lending	(billion)	27.0	32.8	36.9	42.3	43.0	
ROE		10.0%	10.3%	9.1%	8.8%	(10.5%)	

* The figures have been adjusted before 10/1/2017, when stock consolidation to1 from 5 was executed.

Forecasted dividends per share of 135 yen, up 10 yen year-on-year (No revision)

FY2022 Management Plan i) FY2022 Numerical Targets of Denka Value-Up

Operating Income (¥ billions)	FY2020 Actual	FY2021 Initial Forecast	FY2022 Management Plan	Year-on- year	Main measures		
Electronics & Innovative Products	14.2	17.0	22.0	+5.0	 Spherical alumina: Increasing xEV and 5G communications-related demand, effect of expansion in Singapore operations (to be completed around the end of fiscal 2021) Acetylene black: Increasing demand for xEV and high-voltage offshore wind power generation cables, shift from low-cost applications to high-value-added applications 		
Life Innovation	14.8	10.5	11.0	+0.5	Influenza vaccine: New facilities production operations from 2022 season Test reagents: Product line-up expansions, testing demand recovery (CRP for China, etc.) COVID-19 test kit: Estimated drop in prices the DELYTACT (G47Δ) Oncolytic Virus: Expected to contribute in FY2023 and beyond		
Elastomer & Infrastructure Solutions	-3.6	4.0	7.0	+3.0	Chloroprene rubber: Recovery in demand Cement: Increasing resource recycling (acceptance in municipal waste) Specialty admixtures: Increasing demand in "the linear shinkansen", by promoting sales of "Clear Shot", dust control product used in tunnel construction		
Polymer Solutions	8.4	9.5	11.0	+1.5	MS resin: Increasing demand in light guide plates in TVs and monitors as well as in lighting, and expanding demand in other applications such as cosmetic containers Production capacity in Singapore doubled (operation started in July) IP: Expanding sales of high value-added grades (for automotive interior/exterior materials, etc.)		
Others	0.8	1.0	-1.0	-2.0	(Includes increasing labor costs resulting from better labor conditions throughout the entire Group)		
Total	34.7	42.0	50.0	+8.0	* DELYTACT is a registered trademark of Daiichi Sankyo Company, Limited		
Complete the specialty strategy of Depka Value Up							

Complete the specialty strategy of Denka Value-Up to achieve 50 billion yen in operating income

Copyright © Denka Co., Ltd. All Rights Reserved. 21

Denka

Cautionary statement regarding forward-looking information

Target figures in this material are not forecasts of business results. In addition, any description relating to the future in this material is subject to known or unknown risks and uncertainties,

- although it is base on management's current assumptions and beliefs in light of the information currently available to it.
- Please be cautioned that a number of important factors could cause actual results to differ significantly from the description in the material.

Such risks and uncertainties include adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launch, pricing, and product initiatives of competitors, the inability of the Company to market existing and new products effectively, interruptions in production, infringements of the company's intellectual property rights and the adverse outcome of material litigation. Possibility of chemistry



Inquiries regarding this material

Corporate Communications Dept, Denka Co., Ltd.

